-
Mashup Score: 0Remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy - 1 year(s) ago
Han Zhu, MD, Stanford University, Standford, CA, discusses remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy. Fatality…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
CTX130 yields sustained complete response in one patient with relapsed/refractory disease
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
"In a sense, this is a transplant unmatched therapy, so it is very exciting that this has really worked so well." -- Pamela Ohashi, PhD, of @pmcancercentre. https://t.co/KVxIBte6ZX #SITC2022
-
-
Mashup Score: 0
Judith Varner, PhD, University of California, San Diego, CA, discusses the latest developments in targeting myeloid cells for cancer immunotherapy…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @JudithVarner2 of @UCSanDiego talks on the latest developments in immunotherapeutic targeting myeloid cells Watch: 👉https://t.co/oze1XHo4xp👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 4Radiomic texture patterns on CT scans as biomarker of early response to CDK4/6 inhibitors in HR+ mBC - 1 year(s) ago
Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses changes in radiomic texture patterns on CT scans as…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Anant Madabhushi (@anantm) of @EmoryMedicine discusses changes in radiomic texture patterns on CT scans as a biomarker of early response to CDK 4/6 inhibitors in HR+ metastatic breast cancer Watch: 👉https://t.co/d21M4QlKBi👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 0Risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors - 1 year(s) ago
Han Zhu, MD, Stanford University, Standford, CA, discusses risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors….
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @HanZhuMD of @Stanford discusses risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors Watch: 👉https://t.co/2QL384asN3👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 0Key updates in immunotherapies for melanoma - 1 year(s) ago
Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses recent advances in the field of immunotherapy for patients with…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @diwakardavar of @UPMCHillmanCC discusses key updates in immunotherapies for melanoma Watch: 👉https://t.co/fm505cPzx8👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 1PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer - 1 year(s) ago
PDS0101 given in conjunction with chemoradiation elicited an 100% overall response rate, along with tumor shrinkage greater than 60%, in 9 patients with high-risk, locally advanced cervical cancer, according to results of the phase 2 IMMUNOCERV trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer @sitcancer #SITC2022 #gynsm https://t.co/xgoNC38y83 https://t.co/lKzhP7JtG6
-
-
Mashup Score: 0The role of myeloid cells in TME - 1 year(s) ago
Judith Varner, PhD, University of California, San Diego, CA, discusses the role of myeloid cells in the tumor microenvironment (TME)…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @JudithVarner2 of @UCSanDiego discusses the role of myeloid cells in TME Watch: 👉https://t.co/zSCnBw633T👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 0Collagen fiber + immune architecture as novel biomarker for gynecological cancers treated with IO - 1 year(s) ago
Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses the association between the combination of novel biomarkers of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Anant Madabhushi (@anantm) of @EmoryMedicine talks on collagen fiber + immune architecture as novel biomarker for gynecological cancers treated with IO Watch: 👉https://t.co/3HY8ZICrUn👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
-
Mashup Score: 1
Han Zhu, MD, Stanford University, Standford, CA, discusses immune-mediated mechanisms in checkpoint inhibitor-induced myocarditis and investigating druggable targets as well…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @HanZhuMD of @Stanford talks on predicting the development of myocarditis and investigating druggable targets Watch: 👉https://t.co/5dXAT71Dry👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc
-
🎥 @HanZhuMD of @Stanford discusses remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy Watch: 👉https://t.co/fnDyhK5oG6👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc